|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Dyax Corporation
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Dyax, a development stage biopharmaceutical company, is focused on developing and commercializing products for inflammatory and oncology indications. The company, through its proprietary drug discovery technology, known as phage display, identifies antibody, small protein and peptide compounds for clinical development.
Dyax's Kalbitor (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the five company over the last years.
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Company Financials: Incyte
Company Financials: Abbott Laboratories
Company Financials: DURECT Corporation
Company Financials: Momenta Pharmaceuticals
Company Financials: Medivation
Company Financials: DUSA Pharmaceuticals, Inc.
Company Financials: ImmunoGen, Inc.
Company Financials: Alkermes, Inc.
Company Financials: Idenix Pharmaceuticals, Inc.
Company Financials: Genta Incorporated
|
|
|
|
